Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79951 | 0.92 | PPARD (0.40) | PPARGPPARDPPARAS1PR1S1PR4 | |
| SCHEMBL86692 | 0.91 | AAK1 (0.39) | PPARGPPARDPPARAS1PR1S1PR4 | |
| SCHEMBL86443 | 0.91 | AAK1 (0.39) | PPARGPPARDPPARAS1PR1S1PR4 | |
| SCHEMBL86253 | 0.91 | AAK1 (0.39) | PPARGPPARDPPARAS1PR1S1PR4 | |
| SCHEMBL86787 | 0.88 | AAK1 (0.41) | PPARDS1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL86584 | 0.88 | AAK1 (0.40) | PPARGPPARDPPARAS1PR1S1PR4 | |
| SCHEMBL13851949 | 0.87 | S1PR1 (0.52) | S1PR1S1PR4S1PR5S1PR3AAK1 | |
| SCHEMBL79290 | 0.86 | PPARG (0.40) | PPARGPPARDPPARAS1PR1S1PR4 | |
| SCHEMBL79906 | 0.83 | S1PR1 (0.40) | PPARGPPARAS1PR1S1PR4S1PR5 | |
| SCHEMBL79907 | 0.83 | S1PR1 (0.40) | PPARGPPARAS1PR1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | PPARG 1030/4885PPARD 1369/4885PPARA 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.